Cibler aussi le mésothéliome pleural malin et le cancer bronchique à petites cellules ?

Although no targeted agent has been yet approved for MPM or SCLC treatment, a few clinical trials reported encouraging results and some phase III studies are ongoing. Therefore, clinical and translational research efforts must continue.